-
公开(公告)号：US07622560B2
公开(公告)日：2009-11-24
申请号：US11312126
申请日：2005-12-20
Applicant: Seong-Hoe Park , Kyeong-Cheon Jung , Eun-Young Choi , Seong-Pyo Park
Inventor： Seong-Hoe Park , Kyeong-Cheon Jung , Eun-Young Choi , Seong-Pyo Park
IPC: C07K16/00 , C07K16/28 , A61K39/395
CPC classification number: C07K16/3061 , A61K47/6815 , A61K47/6829 , A61K47/6849 , A61K47/6898 , A61K49/0021 , A61K49/0043 , A61K49/0058 , A61K51/1027 , B82Y5/00 , C07K14/70596 , C07K16/2896 , C07K2317/34 , Y10S435/81
Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
Abstract translation: 本发明涉及在人急性白血病和淋巴细胞淋巴瘤细胞上表达的CD43表位及其用途。 更具体地说，本发明涉及在人急性白血病，淋巴细胞淋巴瘤细胞上表达但不在成熟造血细胞，造血干细胞和非造血细胞上表达的CD43表位以及其在急性白血病和淋巴母细胞淋巴瘤上的诊断和治疗应用 。
-
公开(公告)号：US08426555B2
公开(公告)日：2013-04-23
申请号：US12577115
申请日：2009-10-09
Applicant: Seong-Hoe Park , Kyeong-Cheon Jung , Eun-Young Choi , Seong-Pyo Park
Inventor： Seong-Hoe Park , Kyeong-Cheon Jung , Eun-Young Choi , Seong-Pyo Park
IPC: C07K4/00
CPC classification number: C07K16/3061 , A61K47/6815 , A61K47/6829 , A61K47/6849 , A61K47/6898 , A61K49/0021 , A61K49/0043 , A61K49/0058 , A61K51/1027 , B82Y5/00 , C07K14/70596 , C07K16/2896 , C07K2317/34 , Y10S435/81
Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
Abstract translation: 本发明涉及在人急性白血病和淋巴细胞淋巴瘤细胞上表达的CD43表位及其用途。 更具体地说，本发明涉及在人急性白血病，淋巴细胞淋巴瘤细胞上表达但不在成熟造血细胞，造血干细胞和非造血细胞上表达的CD43表位以及其在急性白血病和淋巴母细胞淋巴瘤上的诊断和治疗应用 。
-
3.发明申请ANTIBODY SPECIFIC TO METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS, DETECTION METHOD AND KIT FOR METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS USING THE SAME 有权特异性抗甲氧西林黄曲霉的抗体，使用该抗体的耐甲氧西林金黄色葡萄球菌的检测方法和试剂盒公开(公告)号：US20120070851A1
公开(公告)日：2012-03-22
申请号：US13255115
申请日：2009-06-24
Applicant: Hyung-Geun Song , Sang-Soon Yoon , Hae-Jung Kim , Gil-Yong Jee , Mi-Hyang Shin , Yu-Ri Moon
Inventor： Hyung-Geun Song , Sang-Soon Yoon , Hae-Jung Kim , Gil-Yong Jee , Mi-Hyang Shin , Yu-Ri Moon
IPC: G01N33/577 , C12N5/16 , C07K16/12
CPC classification number: G01N33/56938 , C07K16/1271
Abstract: The present invention relates to an antibody against a protein specifically expressed in methicillin-resistant strains of Staphylococcus aureus (MRSA), and a method and a kit for detecting MRSA. The present invention enables a fast and accurate detection of MRSA by using both a PBP2a-specific antibody for the detection of PBP2a and a Protein A-specific antibody for the detection of Protein A.
Abstract translation: 本发明涉及抗甲氧西林耐药菌株金黄色葡萄球菌（MRSA）中特异性表达的蛋白质的抗体，以及用于检测MRSA的方法和试剂盒。 本发明通过使用用于检测PBP2a的PBP2a特异性抗体和用于检测蛋白A的蛋白A特异性抗体，能够快速准确地检测MRSA。
-
4.发明授权Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof 有权通过结合细胞间粘附分子-1调节树突状细胞的分化和功能的抗体及其用途公开(公告)号：US09115198B2
公开(公告)日：2015-08-25
申请号：US13684160
申请日：2012-11-22
Applicant: DINONA INC.
Inventor： Seong-Hoe Park , Kyeong-Cheon Jung , Youngmee Bae , Seong-Pyo Park , Yoon-Kyung Jeon
IPC: C07K16/28
CPC classification number: C07K16/2821
Abstract: The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
Abstract translation: 本发明涉及结合人细胞间粘附分子-1（ICAM-1）的抗体，其中抗体能够调节树突状细胞的分化状态并延长移植物存活。 此外，本发明提供了包含该抗体的药物组合物及其用于治疗疾病的方法。
-
5.发明授权Acute leukemia and lymphoblastic lymphoma-specific CD43 epitope and use thereof 有权急性白血病和淋巴细胞淋巴瘤特异性CD43表位及其用途公开(公告)号：US08753636B2
公开(公告)日：2014-06-17
申请号：US13842942
申请日：2013-03-15
Applicant: Dinona Inc.
Inventor： Seong-Hoe Park , Kyeong-Cheon Jung , Eun-Young Choi , Seong-Pyo Park
IPC: A61K39/395
CPC classification number: C07K16/3061 , A61K47/6815 , A61K47/6829 , A61K47/6849 , A61K47/6898 , A61K49/0021 , A61K49/0043 , A61K49/0058 , A61K51/1027 , B82Y5/00 , C07K14/70596 , C07K16/2896 , C07K2317/34 , Y10S435/81
Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
Abstract translation: 本发明涉及在人急性白血病和淋巴细胞淋巴瘤细胞上表达的CD43表位及其用途。 更具体地说，本发明涉及在人急性白血病，淋巴细胞淋巴瘤细胞上表达但不在成熟造血细胞，造血干细胞和非造血细胞上表达的CD43表位以及其在急性白血病和淋巴母细胞淋巴瘤上的诊断和治疗应用 。
-
Patent Agency Ranking
6.发明申请EPITOPE OF CD66C SPECIFIC TO LUNG ADENOCARCINOMA AND ANTIBODY RECOGNIZING THE SAME 有权CD66C特异性肺腺癌和抗体识别其抗体公开(公告)号：US20110212095A1
公开(公告)日：2011-09-01
申请号：US12868811
申请日：2010-08-26
Applicant: Hyung-Geun SONG , Sang-Sun Yoon , Mi-Hyang Shin , Yu-Ri Moon
Inventor： Hyung-Geun SONG , Sang-Sun Yoon , Mi-Hyang Shin , Yu-Ri Moon
IPC: A61K39/395 , C07K7/08 , C07K16/30 , C12N5/16 , G01N33/574 , A61P35/00
CPC classification number: G01N33/57423 , A61K2039/505 , C07K14/70503 , C07K16/2803 , C07K16/30 , C07K2317/34 , C07K2319/30
Abstract: The present invention relates to epitope of CD66c specific to lung adenocarcinoma and antibody recognizing the same. The present invention relates to identifying epitope of CD66c specific to lung adenocarcinoma, antibody recognizing the same, cell lines producing the same and the applications in diagnosis, prevention and treatment of lung adenocarcinoma by using the same. The above CD66c epitope is specific to lung adenocarcinoma cells, and therefore the antibody or its fragment recognizing the epitope can be used in compositions to diagnose, treat and prevent lung adenocarcinoma cells.
Abstract translation: 本发明涉及肺腺癌特异性的CD66c表位和识别其的抗体。 本发明涉及鉴定肺腺癌特异性的CD66c表位，识别其的抗体，产生该抗体的细胞系以及通过使用该腺癌诊断，预防和治疗肺腺癌的应用。 上述CD66c表位对肺腺癌细胞是特异性的，因此识别表位的抗体或其片段可用于诊断，治疗和预防肺腺癌细胞的组合物中。
-
7.发明申请ACUTE LEUKEMIA AND LYMPHOBLASTIC LYMPHONA-SPECIFIC CD43 EPITOPE AND USE THEREOF 有权急性淋巴细胞白血病和淋巴细胞淋巴瘤特异性CD43表达及其用途公开(公告)号：US20100234562A1
公开(公告)日：2010-09-16
申请号：US12577115
申请日：2009-10-09
Applicant: SEONG-HOE PARK , KYEONG-CHEON JUNG , EUN-YOUNG CHOI , SEONG-PYO PARK
Inventor： SEONG-HOE PARK , KYEONG-CHEON JUNG , EUN-YOUNG CHOI , SEONG-PYO PARK
IPC: C07K14/435
CPC classification number: C07K16/3061 , A61K47/6815 , A61K47/6829 , A61K47/6849 , A61K47/6898 , A61K49/0021 , A61K49/0043 , A61K49/0058 , A61K51/1027 , B82Y5/00 , C07K14/70596 , C07K16/2896 , C07K2317/34 , Y10S435/81
Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
Abstract translation: 本发明涉及在人急性白血病和淋巴细胞淋巴瘤细胞上表达的CD43表位及其用途。 更具体地说，本发明涉及在人急性白血病，淋巴细胞淋巴瘤细胞上表达但不在成熟造血细胞，造血干细胞和非造血细胞上表达的CD43表位以及其在急性白血病和淋巴母细胞淋巴瘤上的诊断和治疗应用 。
-
8.发明申请Acute Leukemia And Lymphoblastic Lymphoma-Specific CD43 Epitope and Use Thereof 审中-公开急性白血病和淋巴细胞淋巴瘤特异性CD43表位及其用途公开(公告)号：US20140342374A1
公开(公告)日：2014-11-20
申请号：US14269018
申请日：2014-05-02
Applicant: Dinona Inc.
Inventor： Seong-Hoe Park , Kyeong-Cheon Jung , Eun-Young Choi , Seong-Pyo Park
IPC: G01N33/574
CPC classification number: G01N33/57426 , A61K47/6815 , A61K47/6829 , A61K47/6849 , A61K47/6898 , A61K49/0021 , A61K49/0043 , A61K49/0058 , A61K51/1027 , B82Y5/00 , C07K14/70596 , C07K16/2896 , C07K2317/34 , G01N2333/70596
Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.
Abstract translation: 本发明涉及在人急性白血病和淋巴细胞淋巴瘤细胞上表达的CD43表位及其用途。 更具体地说，本发明涉及在人急性白血病，淋巴细胞淋巴瘤细胞上表达但不在成熟造血细胞，造血干细胞和非造血细胞上表达的CD43表位以及其在急性白血病和淋巴母细胞淋巴瘤上的诊断和治疗应用 。
-
9.发明申请Antibody Modulating The Differentiation And Function Of Dendritic Cells Via Binding Intercellular Adhesion Molecule-1 And Use Thereof 审中-公开抗体通过结合细胞间粘附分子-1调节树突状细胞的分化和功能及其用途公开(公告)号：US20130142811A1
公开(公告)日：2013-06-06
申请号：US13684160
申请日：2012-11-22
Applicant: Dinona Inc.
Inventor： Seong-Hoe Park , Kyeong-Cheon Jung , Youngmee Bae , Seong-Pyo Park , Yoon-Kyung Jeon
IPC: C07K16/28
CPC classification number: C07K16/2821
Abstract: The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
Abstract translation: 本发明涉及结合人细胞间粘附分子-1（ICAM-1）的抗体，其中抗体能够调节树突状细胞的分化状态并延长移植物存活。 此外，本发明提供了包含该抗体的药物组合物及其用于治疗疾病的方法。
-
10.发明授权Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same 有权CD66C表位特异性肺腺癌和抗体识别相同公开(公告)号：US08404812B2
公开(公告)日：2013-03-26
申请号：US12868811
申请日：2010-08-26
Applicant: Hyung-Geun Song , Sang-Sun Yoon , Mi-Hyang Shin , Yu-Ri Moon
Inventor： Hyung-Geun Song , Sang-Sun Yoon , Mi-Hyang Shin , Yu-Ri Moon
IPC: C07K16/00 , C12N5/07 , G01N33/53 , A61K39/395
CPC classification number: G01N33/57423 , A61K2039/505 , C07K14/70503 , C07K16/2803 , C07K16/30 , C07K2317/34 , C07K2319/30
Abstract: The present invention relates to epitope of CD66c specific to lung adenocarcinoma and antibody recognizing the same. The present invention relates to identifying epitope of CD66c specific to lung adenocarcinoma, antibody recognizing the same, cell lines producing the same and the applications in diagnosis, prevention and treatment of lung adenocarcinoma by using the same. The above CD66c epitope is specific to lung adenocarcinoma cells, and therefore the antibody or its fragment recognizing the epitope can be used in compositions to diagnose, treat and prevent lung adenocarcinoma cells.
Abstract translation: 本发明涉及肺腺癌特异性的CD66c表位和识别其的抗体。 本发明涉及鉴定肺腺癌特异性的CD66c表位，识别其的抗体，产生该抗体的细胞系以及通过使用该腺癌诊断，预防和治疗肺腺癌的应用。 上述CD66c表位对肺腺癌细胞是特异性的，因此识别表位的抗体或其片段可用于诊断，治疗和预防肺腺癌细胞的组合物中。
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.012 seconds)
